1. Academic Validation
  2. Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs

Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs

  • J Cell Sci. 2022 Mar 1;135(5):jcs259002. doi: 10.1242/jcs.259002.
Asmahan Abu-Arish 1 2 Elvis Pandžić 3 Yishan Luo 1 2 Yukiko Sato 1 2 Mark J Turner 1 2 Paul W Wiseman 4 5 John W Hanrahan 1 2 6
Affiliations

Affiliations

  • 1 Department of Physiology, McGill University, Montréal, QC H3G 1Y6, Canada.
  • 2 Cystic Fibrosis Translational Research Centre, McGill University, Montréal, QC H3G 1Y6, Canada.
  • 3 UNSW Australia, Biomedical Imaging Facility, Mark Wainwright Analytical Center, Sydney 2052, Australia.
  • 4 Department of Physics, McGill University, Montréal, QC H3A 2T8, Canada.
  • 5 Department of Chemistry, McGill University, Montréal, QC H3A 0B8, Canada.
  • 6 Research Institute of the McGill University Health Centre, McGill University, Montréal, QC H3H 2R9, Canada.
Abstract

Membrane proteins often cluster in nanoscale membrane domains (lipid rafts) that coalesce into ceramide-rich platforms during cell stress, however the clustering mechanisms remain uncertain. The cystic fibrosis transmembrane conductance regulator (CFTR), which is mutated in cystic fibrosis (CF), forms clusters that are Cholesterol dependent and become incorporated into long-lived platforms during hormonal stimulation. We report here that clustering does not involve known tethering interactions of CFTR with PDZ domain proteins, filamin A or the actin Cytoskeleton. It also does not require CFTR palmitoylation but is critically dependent on membrane lipid order and is induced by detergents that increase the phase separation of membrane lipids. Clustering and integration of CFTR into ceramide-rich platforms are abolished by the disease mutations F508del and S13F and rescued by the CFTR modulators elexacaftor plus tezacaftor. These results indicate CF therapeutics that correct mutant protein folding restore both trafficking and normal lipid interactions in the plasma membrane. This article has an associated First Person interview with the first author of the paper.

Keywords

Ceramide; Cholesterol; Cystic fibrosis; Filamin A; PDZ-motif; Trikafta.

Figures
Products